ClinicaliQ Trial Snapshot
- A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A — Recruiting • Phase I • NCT07220564.
- Trial testing whether new medicine Inno8 is safe and effective at different doses for haemophilia A patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks. Conditions: Haemophilia A Interventions: NNC0442-0344 A Lead Sponsor: Novo Nordisk A/S Planned Enrollment: 30 participants